Literature DB >> 20714176

Pathophysiology of macular edema.

Stefan Scholl1, Janna Kirchhof, Albert J Augustin.   

Abstract

Macular edema is defined as an accumulation of fluid in the outer plexiform layer and the inner nuclear layer as well as a swelling of Müller cells of the retina. It consists of a localized expansion of the retinal extracellular space (sometimes associated with the intracellular space) in the macular area. Macular edema is a common cause of a sudden or chronic decrease in visual acuity occurring in many ocular diseases such as age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. As a nonspecific sign of many intraocular and systemic diseases, macular edema represents a common final pathway. The existence of the blood-retinal barrier (BRB) formed by intercellular junctions is the precondition required to maintain this physiological status. This status may become severely disturbed by many diseases, finally resulting in macular edema. In this article, the development of macular edema will also be classified by its pathophysiological and pathobiochemical pathways. Vascular components, the dysfunctional BRB, the role of proteins and water fluxes as well as the role of several inflammatory mediators (e.g. angiotensin II, vascular endothelial growth factor, prostaglandins) in the retina will be discussed as responsible mechanisms leading to the development of macular edema. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714176     DOI: 10.1159/000315155

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  36 in total

1.  In vivo adaptive optics microvascular imaging in diabetic patients without clinically severe diabetic retinopathy.

Authors:  Stephen A Burns; Ann E Elsner; Toco Y Chui; Dean A Vannasdale; Christopher A Clark; Thomas J Gast; Victor E Malinovsky; Anh-Danh T Phan
Journal:  Biomed Opt Express       Date:  2014-02-27       Impact factor: 3.732

2.  Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.

Authors:  Vasileios Konidaris; Zahra Al-Hubeshy; Konstantinos T Tsaousis; Konstantina Gorgoli; Somnath Banerjee; Theodoros Empeslidis
Journal:  Int Ophthalmol       Date:  2017-04-12       Impact factor: 2.031

3.  Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Authors:  Jeffrey M Gelfand; Rachel Nolan; Daniel M Schwartz; Jennifer Graves; Ari J Green
Journal:  Brain       Date:  2012-04-25       Impact factor: 13.501

Review 4.  Optical coherence tomography imaging in uveitis.

Authors:  Sumru Onal; Ilknur Tugal-Tutkun; Piergiorgio Neri; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2013-07-09       Impact factor: 2.031

5.  Venous oxygen saturation is reduced and variable in central retinal vein occlusion.

Authors:  Thorunn Scheving Eliasdottir; David Bragason; Sveinn Hakon Hardarson; Gudrun Kristjansdottir; Einar Stefánsson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-18       Impact factor: 3.117

6.  Proceedings of the 2019 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Mark F Cesta; Torrie A Crabbs; Kyathanahalli S Janardhan; Gregory A Krane; Debabrata Mahapatra; Erin M Quist; Matthias Rinke; George W Schaaf; Gregory S Travlos; Haoan Wang; Cynthia J Willson; Jeffrey C Wolf
Journal:  Toxicol Pathol       Date:  2019-10-23       Impact factor: 1.902

7.  Managing diabetic macular edema: The leading cause of diabetes blindness.

Authors:  Pedro Romero-Aroca
Journal:  World J Diabetes       Date:  2011-06-15

8.  Hyperthermia-induced upregulation of vascular endothelial growth factor in retinal pigment epithelial cells is regulated by mitogen-activated protein kinases.

Authors:  Hendrik Faby; Jost Hillenkamp; Johann Roider; Alexa Klettner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-22       Impact factor: 3.117

9.  Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Heshmatollah Ghanbari; Farzan Kianersi; Seyed Ali Sonbolestan; Mohammad-Ali Abtahi; Mojataba Akbari; Zahra-Alsadat Abtahi; Seyed-Hossein Abtahi
Journal:  Int Ophthalmol       Date:  2016-09-13       Impact factor: 2.031

10.  Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion.

Authors:  Joon-Won Kang; Hyungwoo Lee; Hyewon Chung; Hyung Chan Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-01       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.